1
|
Boogaerts HLF, Smits P, Hans G, Bouly L, Coeck E, Vandamme S, Jansens H, Goossens H, Matheeussen V. Laboratory analysis of two Delta SARS-CoV-2 variant outbreaks in the Port of Antwerp. Acta Clin Belg 2021; 77:925-932. [PMID: 34851231 DOI: 10.1080/17843286.2021.2010966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
INTRODUCTION The B.1.617.2 SARS-CoV-2 or Delta variant, first detected in India, has shown a rapid global spread due to its high transmissibility and now represents more than 99% of the currently circulating variants in Europe. METHODS AND RESULT In May 2021, two ships that had recently arrived in the Port of Antwerp reported crew members with COVID-like symptoms. SARS-CoV-2 RNA was detected in nasopharyngeal swabs in 30 out of 45 skippers and the B.1.617.2 variant was identified via whole genome sequencing. Crew members were isolated or quarantined and repeatedly tested to assess the evolution of their SARS-CoV-2 viral load based on the cycle threshold (CT) values of the PCR reaction. Viral cultures were also taken at day 7 to detect viable virus and were compared with the subjects CT value at that moment. The shipper's clinical condition was closely observed using a digital home monitoring tool. Eleven crew members (37%) required hospitalization, with CT values of SARS-CoV-2 RNA being a good predictive factor for the hospitalization need. Furthermore, a clear correlation between CT values and positive viral culture was observed, hinting infectiousness even longer than 10 days after the intitial positive PCR test. CONCLUSION Our study of 2 Delta variant clusters shows that the initial CT value is a good predictor for hospitalization need and suggests that patients infected with this variant may remain infectious for a longer time period.
Collapse
Affiliation(s)
- Hélène L. F. Boogaerts
- Department of Microbiology and National Reference Centre for Respiratory Pathogens, Antwerp University Hospital (UZA), Edegem, Belgium
| | - Patrick Smits
- Department of Infection Prevention, Flemish Agency for Care and Health, Antwerp, Belgium
| | - Guy Hans
- Multidisciplinary Pain Center (PCT), Antwerp University Hospital (UZA), Edegem, Belgium
| | - Liza Bouly
- Department of Infection Prevention, Flemish Agency for Care and Health, Antwerp, Belgium
| | - Eline Coeck
- Department of Infection Prevention, Flemish Agency for Care and Health, Antwerp, Belgium
| | - Sarah Vandamme
- Department of Microbiology and National Reference Centre for Respiratory Pathogens, Antwerp University Hospital (UZA), Edegem, Belgium
| | - Hilde Jansens
- Department of Microbiology and National Reference Centre for Respiratory Pathogens, Antwerp University Hospital (UZA), Edegem, Belgium
- Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium
- Department of Infection Prevention, Antwerp University Hospital (UZA), Edegem, Belgium
| | - Herman Goossens
- Department of Microbiology and National Reference Centre for Respiratory Pathogens, Antwerp University Hospital (UZA), Edegem, Belgium
- Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium
| | - Veerle Matheeussen
- Department of Microbiology and National Reference Centre for Respiratory Pathogens, Antwerp University Hospital (UZA), Edegem, Belgium
- Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium
- Department of Medical Biochemistry, University of Antwerp, Wilrijk, Belgium
| |
Collapse
|